107 related articles for article (PubMed ID: 10885606)
1. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
Rougier P; Adenis A; Ducreux M; de Forni M; Bonneterre J; Dembak M; Clouet P; Lebecq A; Baille P; Lefresne-Soulas F; Blanc C; Armand JP
Eur J Cancer; 2000 May; 36(8):1016-25. PubMed ID: 10885606
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
3. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study.
Papakostas P; Kouroussis C; Androulakis N; Samelis G; Aravantinos G; Kalbakis K; Sarra E; Souglakos J; Kakolyris S; Georgoulias V
Eur J Cancer; 2001 Oct; 37(15):1833-8. PubMed ID: 11576836
[TBL] [Abstract][Full Text] [Related]
4. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.
Lenzi R; Yalcin S; Evans DB; Abbruzzese JL
Cancer Invest; 2002; 20(4):464-72. PubMed ID: 12094541
[TBL] [Abstract][Full Text] [Related]
6. A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer.
Syrigos KN; Michalaki B; Alevyzaki F; Machairas A; Mandrekas D; Kindilidis K; Karatzas G
Anticancer Res; 2002; 22(6B):3583-8. PubMed ID: 12552960
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
[TBL] [Abstract][Full Text] [Related]
9. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
Kotsakis A; Matikas A; Koinis F; Kentepozidis N; Varthalitis II; Karavassilis V; Samantas E; Katsaounis P; Dermitzaki EK; Hatzidaki D; Mavroudis D; Georgoulias V
Br J Cancer; 2016 Sep; 115(7):784-8. PubMed ID: 27607471
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel delivers new management opportunities for gastrointestinal carcinomas.
Rougier P
Anticancer Drugs; 1995 Jul; 6 Suppl 4():25-9. PubMed ID: 8745351
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study.
Androulakis N; Kourousis C; Dimopoulos MA; Samelis G; Kakolyris S; Tsavaris N; Genatas K; Aravantinos G; Papadimitriou C; Karabekios S; Stathopoulos GP; Georgoulias V
J Clin Oncol; 1999 Jun; 17(6):1779-85. PubMed ID: 10561215
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
Perng RP; Shih JF; Chen YM; Chou KC; Lee YC; Tsai CM
Jpn J Clin Oncol; 2000 Oct; 30(10):429-34. PubMed ID: 11185888
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
Bang YJ; Kang WK; Kang YK; Kim HC; Jacques C; Zuber E; Daglish B; Boudraa Y; Kim WS; Heo DS; Kim NK
Jpn J Clin Oncol; 2002 Jul; 32(7):248-54. PubMed ID: 12324575
[TBL] [Abstract][Full Text] [Related]
16. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
Georgoulias V; Androulakis N; Dimopoulos AM; Kourousis C; Kakolyris S; Papadakis E; Apostolopoulou F; Papadimitriou C; Vossos A; Agelidou M; Heras P; Tzannes S; Vlachonicolis J; Mavromanolakis E; Hatzidaki D
Ann Oncol; 1998 Mar; 9(3):331-4. PubMed ID: 9602269
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.
Bonneterre J; Spielman M; Guastalla JP; Marty M; Viens P; Chollet P; Roché H; Fumoleau P; Mauriac L; Bourgeois H; Namer M; Bergerat JP; Misset JL; Trandafir L; Mahjoubi M
Eur J Cancer; 1999 Oct; 35(10):1431-9. PubMed ID: 10673974
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.
Kurtz JE; Négrier S; Husseini F; Limacher JM; Borel C; Wagner JP; Prévot G; Bergerat JP; Dufour P
Hepatogastroenterology; 2003; 50(50):567-70. PubMed ID: 12749274
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
